Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study
Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
Stocks · News reference
Corcept Therapeutics Announces Positive Phase 2 BELLA Trial Results for Lifyorli Combination in Ovarian Cancer
Corcept Therapeutics reported positive results from its Phase 2 BELLA trial, showing that the combination of Lifyorli with nab-paclitaxel and bevacizumab slowed disease progression in patients with platinum-resistant ovarian cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Corcept Therapeutics Says ADA And EASD Recommend Hypercortisolism Screening In Difficult-To-Control Type 2 Diabetes, Citing Its CATALYST Mifepristone Trial
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.